WESTON, Fla., March 12, 2018 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. ("Cantex"), a clinical stage biopharmaceutical
The paper, titled "Combination of the Low Anticoagulant Heparin CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia," reported results from Cantex's pilot study of CX-01 in combination with chemotherapy (cytarabine and idarubicin given on a "7 + 3" schedule) for the treatment of AML. Data from the study indicated that 92% (11 of 12) of patients achieved a complete remission following a single induction cycle of CX-01 in combination with chemotherapy treatment. Additionally, hematologic recovery appeared to be enhanced, with a median of 22 days to reach an absolute neutrophil count (ANC) of 0.5 x 109/L or higher, and 21 days to reach a platelet count higher than 20 x 109 /L in induction cycles.
The study was conducted at Huntsman Cancer Institute (HCI) at the University of Utah, the Medical University of South Carolina, and Augusta University. HCI was the lead cancer center for this trial. The design was developed by Paul Shami, MD, and Tibor Kovacsovics, MD, at HCI and their colleagues at the other study centers.
Stephen Marcus, M.D., Chief Executive Officer of Cantex and a co-author of the paper, stated, "Results from the pilot study suggest that CX-01 in combination with chemotherapy could provide a potentially efficacious therapy for the treatment of AML. Not only did the study produce highly encouraging remission rates after a single induction cycle of chemotherapy, but the therapy also suggested a more rapid white blood cell and platelet count recovery, which is important to recovery from intensive chemotherapy."
Based upon the results of this study, Cantex is currently conducting a 75-patient randomized Phase IIb study in more than 20 U.S. medical centers to determine whether CX-01 can enhance the efficacy of front-line chemotherapy of AML. Top-line results from this study are expected later this year. In January of this year, the U.S. Food and Drug Administration granted Orphan Drug Designation to CX-01 for the treatment of AML.
For access to the full paper in Blood AdvancesŪ, please proceed to: http://www.bloodadvances.org/content/2/4/381
An additional Phase II study in refractory myelodysplastic syndrome and refractory AML is in progress at Washington University in St. Louis.
About Cantex Pharmaceuticals, Inc.Cantex is a clinical stage biopharmaceutical company focused on developing and commercializing proprietary compounds that enhance the efficacy and safety of the treatment of cancer and other life-threatening disorders. Cantex's product candidate, CX-01, is a multi-targeted new chemical entity in development for the treatment of AML and myelodysplastic syndrome. Cantex's other clinical stage product, Dicopp, a proprietary combination of disulfiram + copper, is currently in clinical trials for recurrent glioblastoma and metastatic castration-resistant prostate cancer. For more information, please visit www.cantex.com.
Media Contact: Jason Rando Tiberend Strategic Advisors, Inc. 212-375-2665 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/publication-in-blood-advances-reports-that-the-combination-of-cantex-pharmaceuticals-cx-01-with-chemotherapy-for-the-treatment-of-acute-myeloid-leukemia-showed-encouraging-complete-remission-rates-and-rapid-platelet-count-recove-300611940.html
SOURCE Cantex Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!